Drug intelligence / Profile preview

Ipomoea aquatica-derived exosome-like nanoparticles

Development stage
Preclinical
Lead developer
Korea Atomic Energy Research Institute
Modality
Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01

Overview

Ipomoea aquatica-derived exosome-like nanoparticles (IA-ELNs) are plant-derived extracellular-like nanoparticles isolated from the leaves of *Ipomoea aquatica* (water spinach). Developed by the Korea Atomic Energy Research Institute, these nanoparticles are being investigated for their potential in cancer immunotherapy. IA-ELNs function by activating dendritic cells (DCs) and promoting Th1-polarized anti-tumor immune responses. Mechanistically, they enhance DC maturation by upregulating surface markers such as CD80, CD86, MHC-I, and MHC-II, and stimulating the secretion of pro-inflammatory cytokines like IL-12p70 and TNF-α. This activation is mediated through the phosphorylation of ERK, JNK, and p38 MAPKs, as well as the activation of the NF-κB signaling pathway, ultimately leading to the proliferation of CD4+ and CD8+ T cells.

Other names
IA-ELNsIpomoea aquatica-derived extracellular-like nanoparticleswater spinach-derived exosome-like nanoparticleswater spinach-derived extracellular-like nanoparticles
02

Targets

MAPK14 (p38 mitogen-activated protein kinase alpha)MAPK3 (Mitogen-activated protein kinase 1)JNK (Mitogen-activated protein kinase kinase kinase family)NF-κB

Beyond the preview

Go deeper on Ipomoea aquatica-derived exosome-like nanoparticles.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ipomoea aquatica-derived exosome-like nanoparticles.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call